|
If PT141 is approved by the FDA in 2007 it will have the most revolutionary
effect on women’s sex lives since the availability of the birth control pill in
the early 1960’s. Unlike sexual enhancement drugs for men such as Viagra,
Levitra, and Cialis, there are no drugs currently available for women with
sexual dysfunction problems. If current studies being conducted by Palatin
Technologies on the treatment of female sexual dysfunction problems are any
indication, PT141 could be the first drug available to boost female sexual
desire. Tests conducted on rats have shown “significantly enhanced” sexual
behavior. What scientists have observed is that when given PT141, female rats
actually sought male rats for sex. Jim Pfaus, a professor of psychology at
Concordia University in Montreal, who along with Palatin Technologies has been
researching PT141, believes it “could be bigger than Viagra.”
Palatin has conducted a two phase study with 50 pre-menopausal without sexual
dysfunction and found that women taking PT141 reported an increase in their
level of sexual desire and genital arousal compared to a placebo.
Because female sexual dysfunction involves problems with desire, arousal, orgasm
and pain, PT141 could be beneficial for both women with female sexual
dysfunction (women who are interested in sex, but cannot reach a climax) as well
as women who have a lack of desire for sex and not physiological problems. This
is because PT141 works to activate receptors in the central nervous system to
increase desire for sex while also increasing blood flow to the genital area
thus improving both sexual desire and sexual function
With the aging “baby boom” generation, both men and women who suffer from sexual
dysfunction are a growing market and PT141 shows potential to be more effective
than Viagra in treating sexual dysfunction with minimal side effects. Based on
studies thus far, PT141 shows promise to bring new found sexual enjoyment for
women who have suffered from decreased sexual function and have not had the
benefit of sexual enhancement drugs on the market.
|
|
